One treatment naïve NSCLC patient who underwent targeted therapy prior to immunotherapy had a BRAF V600E mutation detected and received both BRAF single agent and combination BRAF/MEK inhibitors. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.